DE3781250D1 - Verwendung vom "cartilage-inducing faktor b(cif-b)" zur herstellung eines arzneimittels gegen das wachstum von tumoren. - Google Patents

Verwendung vom "cartilage-inducing faktor b(cif-b)" zur herstellung eines arzneimittels gegen das wachstum von tumoren.

Info

Publication number
DE3781250D1
DE3781250D1 DE8787309877T DE3781250T DE3781250D1 DE 3781250 D1 DE3781250 D1 DE 3781250D1 DE 8787309877 T DE8787309877 T DE 8787309877T DE 3781250 T DE3781250 T DE 3781250T DE 3781250 D1 DE3781250 D1 DE 3781250D1
Authority
DE
Germany
Prior art keywords
cif
activity
cartilage
tumors
medicinal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE8787309877T
Other languages
English (en)
Other versions
DE3781250T2 (de
Inventor
John M Mcpherson
Daniel R Twardzik
George J Todaro
Karl A Piez
Jane E Ranchalis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oncogen LP
Celtrix Pharmaceuticals Inc
Original Assignee
Oncogen LP
Celtrix Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncogen LP, Celtrix Pharmaceuticals Inc filed Critical Oncogen LP
Publication of DE3781250D1 publication Critical patent/DE3781250D1/de
Application granted granted Critical
Publication of DE3781250T2 publication Critical patent/DE3781250T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1841—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/12—Growth hormone, growth factor other than t-cell or b-cell growth factor, and growth hormone releasing factor; related peptides
DE8787309877T 1986-11-07 1987-11-06 Verwendung vom "cartilage-inducing faktor b(cif-b)" zur herstellung eines arzneimittels gegen das wachstum von tumoren. Expired - Lifetime DE3781250T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/928,760 US4816442A (en) 1986-11-07 1986-11-07 Method of inhibiting tumor growth sensitive to CIF-βtreatment

Publications (2)

Publication Number Publication Date
DE3781250D1 true DE3781250D1 (de) 1992-09-24
DE3781250T2 DE3781250T2 (de) 1992-12-17

Family

ID=25456702

Family Applications (1)

Application Number Title Priority Date Filing Date
DE8787309877T Expired - Lifetime DE3781250T2 (de) 1986-11-07 1987-11-06 Verwendung vom "cartilage-inducing faktor b(cif-b)" zur herstellung eines arzneimittels gegen das wachstum von tumoren.

Country Status (7)

Country Link
US (1) US4816442A (de)
EP (1) EP0271211B1 (de)
JP (1) JP2573259B2 (de)
AT (1) ATE79545T1 (de)
CA (1) CA1294874C (de)
DE (1) DE3781250T2 (de)
ES (1) ES2032272T3 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5705477A (en) * 1982-09-24 1998-01-06 The United States Of America As Represented By The Department Of Health And Human Services Compositions of transforming growth factor β(TGF-β) which promotes wound healing and methods for their use
US5656587A (en) * 1982-09-24 1997-08-12 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Promotion of cell proliferation by use of transforming growth factor beta (TGF-β)
US5104977A (en) * 1982-09-24 1992-04-14 The United States Of America As Represented By The Department Of Health And Human Services Purified transforming growth factor beta
US6586394B1 (en) 1985-04-19 2003-07-01 Osi Pharmaceuticals, Inc. Tissue-derived tumor growth inhibitor
US4931548A (en) * 1987-01-30 1990-06-05 Techne Corporation Heterodimer form of transforming growth factor-beta
US5221734A (en) * 1987-10-01 1993-06-22 Ciba-Geigy Corporation Process for preparing a polypeptide growth factor for milk
KR900700116A (ko) * 1988-04-06 1990-08-11 원본미기재 뼈-유도 단백질
US5268455A (en) * 1989-05-25 1993-12-07 Genentech, Inc. Process for making biologically active polypeptides based on transforming growth factor-βsequences
US5061786A (en) * 1989-05-25 1991-10-29 Genentech, Inc. Biologically active polypeptides based on transforming growth factor-β
US5100378A (en) * 1989-06-09 1992-03-31 Neorx Corporation Enhancement of target cell localization of lymphoid cells
EP0489062A4 (en) * 1989-08-21 1992-08-12 Celtrix Laboratories, Inc. Bone-specific protein
IL95500A (en) * 1989-09-11 1997-03-18 Matrix Pharma ANTI-PROLIFERATIVE COMPOSITIONS CONTAINING TGF-b PROTEIN IN A VISCOUS MATRIX AND THEIR USE
US5147854A (en) * 1990-05-22 1992-09-15 Hoffmann-La Roche Inc. Tgf-b compositions and method
US5322933A (en) * 1992-05-07 1994-06-21 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Crystal structure of TGF-β-2
US5888720A (en) * 1992-10-27 1999-03-30 Yissum Research And Development Company Of The Hebrew University Of Jerusalem In vitro micro-organs
US5531791A (en) * 1993-07-23 1996-07-02 Bioscience Consultants Composition for repair of defects in osseous tissues, method of making, and prosthesis
US6040431A (en) * 1995-06-07 2000-03-21 Stryker Corporation Single chain analogs of the TGF-β superfamily (morphons)
RU2217196C2 (ru) 2002-02-28 2003-11-27 Небольсин Владимир Евгеньевич Способ индукции дифференцировки клеток
WO2005059133A2 (en) * 2003-12-19 2005-06-30 Antisense Pharma Gmbh Combination therapy associating a tgf-breta antagonist with a chemiotherapeutic agent
TWI299257B (en) * 2005-05-16 2008-08-01 Tung Hai Biotechnology Corp γ-POLYGLUTAMIC ACID (γ-PGA, H FORM), γ-POLYGLUTAMATES AND γ-POLYGLUTAMATE HYDROGEL FOR USE AS NUTRITION SUPPLEMENTS IN DIETARY PRODUCTS

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0105014B1 (de) * 1982-09-24 1992-05-20 THE UNITED STATES OF AMERICA as represented by the Secretary United States Department of Commerce Wiederherstellung von Gewebe bei Tieren
WO1984004924A1 (en) * 1983-06-03 1984-12-20 Us Commerce Purified transforming growth factor-beta derived from human platelets and placentas
EP0169016B2 (de) * 1984-07-16 2004-04-28 Celtrix Pharmaceuticals, Inc. Knorpel-induzierende Polypeptid-Faktoren aus Knochen
US4806523A (en) * 1985-08-06 1989-02-21 Collagen Corporation Method of treating inflammation

Also Published As

Publication number Publication date
ATE79545T1 (de) 1992-09-15
CA1294874C (en) 1992-01-28
ES2032272T1 (es) 1993-02-01
EP0271211B1 (de) 1992-08-19
ES2032272T3 (es) 1994-01-16
US4816442A (en) 1989-03-28
EP0271211A2 (de) 1988-06-15
DE3781250T2 (de) 1992-12-17
AU591358B2 (en) 1989-11-30
JPS63211236A (ja) 1988-09-02
AU8067987A (en) 1988-05-12
JP2573259B2 (ja) 1997-01-22
EP0271211A3 (en) 1989-10-18

Similar Documents

Publication Publication Date Title
DE3781250T2 (de) Verwendung vom "cartilage-inducing faktor b(cif-b)" zur herstellung eines arzneimittels gegen das wachstum von tumoren.
AU549481B2 (en) Hair growing agent
EP0190018A3 (en) Use of transforming growth factor to promote wound healing and composition therefor
GR3004229T3 (de)
NO852446L (no) Fremgangsmaate for fremstilling av krystallinsk kalsium-pseudomonat eller hydrat derav.
DE3850154T2 (de) Verwendung von Gepiron zur Herstellung eines pharmazeutischen Präparats zur Behandlung atypischer Depression.
EP0253146A3 (de) Die Verwendung von D-fenfluramin zur Herstellung von Arzneimitteln, zur Behandlung von Depressionen
DE69011586T2 (de) Kristallines r-h-GM-CSF und Verfahren zur Herstellung.
DE69004794D1 (de) Verwendung eines Polypeptids mit Interleukin 2-Aktivität zur Herstellung einer zur Behandlung von einfachen Pleurageschwüren bestimmten pharmazeutischen Zusammensetzung.
DK0487613T3 (da) Megakarycytopiesk faktor
ATE120799T1 (de) Mutein von hst-1 und seine herstellung.
DE69021557D1 (de) Verwendung von derivaten von 9,10-dihydrophenanthren zur herstellung eines antitumoralen medikamentes und neuen derivaten daraus.
HUT60145A (en) Process for producing pharmaceutical composition comprising human interleukin-2 and suitable for treating pneumothorax
NZ226360A (en) Antiviral and antitumoural composition containing 2,6 diamino-3-phenyl-3-phenylazo-pyridine
AU2716592A (en) Treatment of anxiety in benzodiazepine-withdrawn patients

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee